Acrivon Therapeutics
Clinical trials sponsored by Acrivon Therapeutics, explained in plain language.
-
New hope for endometrial cancer: targeted therapy trial opens
Disease control Recruiting nowThis study tests a new drug called ACR-368, given alone or with a low dose of chemotherapy, in people with endometrial cancer. The goal is to see if the drug can shrink tumors. About 400 participants will join this phase 2 trial to check safety and effectiveness.
Phase: PHASE2 • Sponsor: Acrivon Therapeutics • Aim: Disease control
Last updated May 26, 2026 12:06 UTC
-
New hope for advanced tumors: first human trial of ACR-2316 begins
Disease control Recruiting nowThis early-phase study tests a new drug, ACR-2316, in about 100 people with advanced solid tumors that have spread or come back. The main goals are to find a safe dose and check for early signs that the drug shrinks tumors. Participants must have tried no more than three prior tr…
Phase: PHASE1 • Sponsor: Acrivon Therapeutics • Aim: Disease control
Last updated May 26, 2026 12:03 UTC